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Abstract/Background
Chronic lymphocytic leukemia (CLL) is a
chronic incurable B-cell disease that
affects primarily older adults. It is the most
common leukemia in the Western world
and viewed as a heterogenous disease
with a highly variable clinical course.
Approximately 2-10% of CLL patients will
develop aggressive histological
transformation to diffuse large B-cell
lymphoma (DLBCL), commonly
recognized as Richter transformation
(RT), with a transformation rate of 3% to
25% in patients treated with novel
agents.1, 5 The 2008 World Health
Organization defined RT as the
transformation of CLL into a more
aggressive lymphoma.3 Richter
transformation occurs due to
dysregulation of signaling pathways of
CLL cells.1,2,5 Of 2975 pts with advanced
CLL, 103 pts developed RT (3%). Median
OS after RT diagnosis ~ 9 months 6

Purpose
The aim of this poster is to increase
awareness of predictive factors and
associated molecular aberrations in RT.
The poster will provide the diagnostic
criteria needed to promote early
recognition and intervention by advanced
practice providers and clinicians towards
improving patient outcomes.
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TP53 disruption (60-80%
NOTCH1 mutation (30%)
CDKN2A/B (30%)
MYC aberration (30%)5
Trisomy 12
Unmutated IGHV (> 95%)
BCL2 (30%)

Risk Factors for RT
•

•

•

•

•

•

Advanced Rai stage disease (III-IV)
or Binet stage C)
Unmutated immunoglobulin heavy
chain variable IGHV gene
Del (17p), TP53, Trisomy 12,
NOTCH1, c-MYC
Previously treated CLL
Germline genetics
Certain aspects of CLL phase
biology7

*The 2018 iWCLL guidelines suggest testing
of biomarkers on initial evaluation for RT

Clinical Features of RT
Table 1. Presenting Features

Rapidly enlarging bulky lymph nodes

Molecular Features

Associated with Richter
Transformation in CLL
§

§

§

§

§

§

§

Mutations in NOTCH1 –
characterized by Trisomy 12
activating NOTCH1 mutations
NOTCH1 mutations wild-type
less common to develop
transformation.
SF3B1 (associated with nonRichter transformation in CLL) 2
CDKN2A/B loss with or without
MYC abnormalities. CDKN2A
gene encodes p161NK4A
1,4,6
dysregulation of
Unmutated IGHV status
c-MYC aberrations caused by
t(8;14) or other structural
alteration5
BCL2 rearrangements by FISH 5

Fig 1. Gene
Mutations
(Nadeu et
al., 2016)

Fig. 2. Time to RT from Initial CLL Treatment 6

Diagnostic Approaches
Fig. 3. .Diagnostic Criteria for RT 2,5,6

Suspect Richter Transformation?

Obtain Thorough H&P: bulky nodes (> 3

cm), fever, weight loss, ↑fatigue, night
sweats, splenomegaly, bruising,
petechiae, shortness of breath

Assess Pertinent Lab Test Results:
CBC, CMP, NGS panel from peripheral
blood or BM, IGHV mutation status,
Cytogenetics, and BM biopsy

Obtain PET/CT (18-FDG) to assess
for FDG-avid nodes with SUV > 5

If FDG avid node with SUV ≥ 10 cm→
IR excisional node biopsy → confirm
DLBCL → Treatment indicated

Implications for APPs in
Diagnosis of RT
Advanced practice providers (APPs) are
often the initial point of contact on patient
presentation in the clinic setting and should
be cognizant of the following:
§ High risk features in CLL that may lead to
RT
§ Performing a detailed H&P
§ Clinical features on presentation, i.e.,
bulky nodes, fever
§ Past treatment history for CLL
§ Be vigilant in assessing predictive
clinicopathological factors for RT

Conclusions
Richter transformation occurs (2-10%) in
advanced stage, previously treated B CLL
with a transformation rate of 3% to 25% post
treatment . CLL patients who present with
clinical signs of RT should evaluated immediately
with a PET/CT and possible biopsy if indicated.
The intent of this poster presentation is to
promote early recognition and diagnosis of
RT, improve patient outcomes and decrease
mortality in this population.

References
1. Rosati, E., Baldoni, S., De Falco, F., Del Papa, B., Dorillo, E., Rompietti, C., et al. (2018).

Increasing fatigue

NOTCH1 aberrations in chronic lymphocytic leukemia. Frontiers in Oncology, 8, 229
https://doi.org/10.3389/fonc.2018.00229

Unexplained fever

2. Khan, M., Siddiqi, R., & Thompson, P. A. (2018). Approach to Richter transformation of chronic
lymphocytic leukemia in the era of novel therapies. Annals of Hematology, 97, 1-15.
3. Arruga, F., Bracciama, V., Vitale, N., Vaisitti, T., Gizzi, K., Yeomans, A., Coscia, M. et al., (2020).
Bidirectional linkage between the B – cell receptor and NOTCH1 in chronic lymphocytic leukemia and
in Richter’s syndrome: therapeutic implications. Leukemia, 34(2), 462-77.
https://doi.org/10.1038/s41375-019-0571-0.
4. Ding, W. (2018). Richter transformation in the era of novel agents. Hematology American Society of
Hematology Educational Program, 1, 256-263. https://doi.org/10. 1182/asheducation-2018.1.256
5. Wang, Y. & Ding, W. (2020). Richter transformation of chronic lymphocytic leukemia in the era of
novel agents. Clinical Advances in Hematology & Oncology, 18(6), 348-357.
6. Al-Sawafi et al. (2020). Richter transformation in chronic lymphocytic leukemia-

Unexplained weight loss
Shortness of breath
Splenomegaly
Elevated LDH
Anemia
Thrombocytopenia

a pooled analysis of German CLL study group from frontline treatment trials. Leukemia, 35(1), 169-176
7. Kohlhass, V., Blakemore, S. J., Al-Maarri, … et al. (2021). Active Akt signaling triggers CLL toward
Richter transformation via overaciivation of NOTCH1. Blood, 137(5), 646-660.

doi.org://10.1182/blood.2020005734.

